Akagera Medicines Inc, a clinical-stage biopharmaceutical company developing lipid nanoparticle (LNP) therapeutics and vaccines for infectious diseases, announced on Wednesday that the Gates Foundation has expanded its grant supporting the company's dendritic cell-targeted LNP mRNA vaccine for the prevention of tuberculosis (TB).
This award adds USD7,806,414 in funding, bringing the total committed under the grant to USD9,791,826.
The grant continues a preclinical feasibility and development programme first funded in 2023. The expanded funding will support GMP manufacturing of clinical trial material and the IND-enabling toxicology studies ahead of a future regulatory filing and before a first-in-human (FIH) Phase 1 clinical trial.
Akagera's vaccine candidate pairs mRNA-encoded Mycobacterium tuberculosis antigens with an LNP engineered to preferentially deliver its payload to dendritic cells, the immune system's most potent antigen-presenting cells. By directing antigen expression to these cells, the approach is designed to drive the strong, durable T-cell responses believed to be central to protection against TB, while potentially enabling lower doses and improved tolerability.
Merck partners with Isomorphic Labs on AI-driven oncology drug discovery
Dicot Pharma secures EU approval to advance LIB-01 phase 2b study
NFL Biosciences enrolls first participant in Phase 2 smoking cessation trial
Anixa Biosciences and Curia to finalise formulation of breast cancer vaccine for Phase 2 trial
Akagera Medicines receives Gates Foundation grant expansion to advance tuberculosis vaccine
Ten63 Therapeutics launches BEYOND-Alpha early adopter programme
Eloxx Pharmaceuticals publishes Phase 2a exaluren data in nonsense mutation Alport syndrome
Bristol Myers Squibb reports first Phase 3 data for KarXT in Alzheimer's-related psychosis
Pfizer signs licensing agreement with Starna Therapeutics worth up to USD2.63bn
Inhibrx updates clinical data for ozekibart (INBRX-109) in Ewing sarcoma
Dicot Pharma initiates phase 2b clinical study of erectile dysfunction drug candidate
Sobi's Tryngolza for severe hypertriglyceridaemia receives EU approval
Oncoinvent reports favourable interim safety results for Radspherin in phase 2 ovarian cancer trial